journal
Journals Therapeutic Advances in Psycho...

Therapeutic Advances in Psychopharmacology

https://read.qxmd.com/read/38633357/attentional-bias-modification-and-attention-control-training-in-ptsd-a-systematic-review-and-meta-analysis
#1
JOURNAL ARTICLE
Fan Zhang, Chenwei Huang, Wenjie Yan, Hui Ouyang, Weizhi Liu
BACKGROUND: Cognitive models of post-traumatic stress disorder (PTSD) highlighted the effect of maladaptive cognitive processing in the development and maintenance of PTSD. PTSD is related to attentional bias (AB) toward threatening stimuli and greater attentional bias variability (ABV). Attentional bias modification (ABM) and attention control training (ACT) have demonstrated the effect of improving PTSD, but the results of randomized controlled trials (RCTs) are controversial. OBJECTIVES: The current study aimed to evaluate the extent of evidence supporting the efficacy of ABM in the treatment of PTSD...
2024: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/38440104/patient-reported-outcomes-on-sleep-quality-and-circadian-rhythm-during-treatment-with-intravenous-ketamine-for-treatment-resistant-depression
#2
JOURNAL ARTICLE
Raymond Yan, Tyler Marshall, Atul Khullar, Travis Nagle, Jake Knowles, Mai Malkin, Brittany Chubbs, Jennifer Swainson
BACKGROUND: Intravenous (IV) ketamine is a rapid acting antidepressant used primarily for treatment-resistant depression (TRD). It has been suggested that IV ketamine's rapid antidepressant effects may be partially mediated via improved sleep and changes to the circadian rhythm. OBJECTIVES: This study explores IV ketamine's association with changes in patient-reported sleep quality and circadian rhythm in an adult population with TRD. METHODS: Adult patients (18-64 years) with TRD scheduled for IV ketamine treatment were recruited to complete patient rated outcomes measures on sleep quality using the Pittsburgh Sleep Quality Index (PSQI) and circadian rhythm using the Morningness-Eveningness Questionnaire (MEQ)...
2024: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/38415202/erratum-to-history-repeating-guidelines-to-address-common-problems-in-psychedelic-science
#3
(no author information available yet)
[This corrects the article DOI: 10.1177/20451253231198466.].
2024: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/38384595/drug-safety-in-older-patients-with-alcohol-use-disorder-a-retrospective-cohort-study
#4
JOURNAL ARTICLE
Sebastian Schröder, Martin Schulze Westhoff, Tabea Pfister, Johanna Seifert, Stefan Bleich, Felix Koop, Phileas Johannes Proskynitopoulos, Alexander Glahn, Johannes Heck
BACKGROUND: Older patients with alcohol use disorder are at particular risk of developing adverse drug reactions due to multimorbidity, polypharmacy, and altered organ function. OBJECTIVES: In this study, we investigated the frequency and characteristics of potentially serious alcohol-medication interactions, potentially inappropriate medications (PIMs) for older adults, and potential drug-drug interactions (pDDIs) in a population of older patients with alcohol use disorder over a 10-year period...
2024: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/38370363/patients-awareness-of-recovery-mediates-the-link-between-clinical-and-level-of-functional-remission-in-schizophrenia-to-a-larger-extent-in-those-treated-with-long-acting-antipsychotics
#5
JOURNAL ARTICLE
Jasmina Mallet, Clément Dondé, Caroline Dubertret, Philip Gorwood
BACKGROUND: Clinical remission is a step towards functional remission for subjects with schizophrenia. While recovery is both a subjective personal journey and a clinical outcome to be targeted, data on patient self-rated outcomes are scarce. OBJECTIVES: (i) To determine the extent to which the association between clinical and functional remission is mediated by the subjective experience of recovery as reported by patients versus their relatives or their psychiatrist and (ii) to assess differences according to treatment, specifically with oral antipsychotics only versus long-acting injectable antipsychotics (LAIs)...
2024: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/38322010/monoclonal-antibody-precision-therapy-targeting-inflammation-for-bipolar-disorder-a-narrative-review
#6
REVIEW
Shijin Wu, Yuyang Zhou
Bipolar disorder (BD) is a severe mental disorder with various hypotheses regarding its pathogenesis. This article provides a summary of numerous studies on the variations in inflammatory cytokine levels in patients with BD and the effects of treatment with antipsychotics, mood stabilizers, and antidepressants on these levels. In addition, patients with autoimmune diseases who use anti-inflammatory monoclonal antibodies experience symptoms, such as depression, anxiety, and insomnia. These pieces of evidence suggest a potential association between immune inflammation and BD and offer new possibilities for therapy...
2024: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/38249521/corrigendum-to-managing-medical-and-psychiatric-multimorbidity-in-older-patients
#7
(no author information available yet)
[This corrects the article DOI: 10.1177/20451253231195274.].
2024: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/38152569/preliminary-data-from-a-4-year-mirror-image-and-multicentre-study-of-patients-initiating-paliperidone-palmitate-6-monthly-long-acting-injectable-antipsychotic-the-paliperidone-2-per-year-study
#8
JOURNAL ARTICLE
Juan Antonio García-Carmona, Alba García-Pérez, Guillermo Isidro García, Luis Alberto Forcen-Muñoz, Santiago Ovejero García, Rocío Sáez Povedano, Ana Luisa González-Galdámez, Laura Mata Iturralde, Fernando Hernández-Sánchez, Mariluz Ramirez Bonilla, Paloma Fuentes-Pérez, Claudia Ovejas-Catalán, Paula Suárez-Pinilla, Francisco Valdivia-Muñoz, Blanca Fernández Abascal, Miguel Omaña Colmenares, Ángela de Lourdes Martín-Pérez, María Pilar Campos-Navarro, Enrique Baca-García, Sergio Benavente-López, Alberto Raya Platero, Miguel Barberán Navalón, Sergio Sánchez-Alonso, Javier Vázquez-Bourgon, Sofia Pappa
BACKGROUND: Paliperidone palmitate 6-monthly (PP6M) is the first long-acting antipsychotic injectable (LAI) to allow for only two medication administrations per year, though there is presently limited insight into its effectiveness and potential added value in real clinical practice conditions. OBJECTIVES: To present our ongoing study and draw its preliminary data on patient characteristics initiating PP6M and adherence during the first year of treatment. METHODS: The paliperidone 2 per year (P2Y) study is a 4-year, multicentre, prospective mirror-image pragmatic study taking place at over 20 different sites in Europe...
2023: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/38107162/oral-and-long-acting-injectable-antipsychotic-discontinuation-and-relationship-to-side-effects-in-people-with-first-episode-psychosis-a-longitudinal-analysis-of-electronic-health-record-data
#9
JOURNAL ARTICLE
Rashmi Patel, Aimee Brinn, Jessica Irving, Jaya Chaturvedi, Shanmukha Gudiseva, Christoph U Correll, Paolo Fusar-Poli, Philip McGuire
BACKGROUND: Discontinuation of treatment in people with first episode psychosis (FEP) is common, but the extent to which this is related to specific adverse effects of antipsychotic medications is unclear. OBJECTIVES: To investigate whether antipsychotic discontinuation is associated with the prescription of particular antipsychotics and particular adverse effects. DESIGN: Retrospective cohort study. METHODS: We assembled de-identified electronic health record (EHR) data from 2309 adults with FEP who received care from the South London and Maudsley NHS Foundation Trust between 1st April 2008 and 31st March 2019...
2023: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/38022838/psychosocial-interventions-to-improve-adherence-in-depressed-and-anxious-older-adults-prescribed-antidepressant-pharmacotherapy-a-scoping-review
#10
REVIEW
Sarah T Stahl, Joelle Kincman, Jordan F Karp, Marie Anne Gebara
Medication nonadherence in depressed and anxious older adults is prevalent and associated with non-response to antidepressant pharmacotherapy. Evidence-based options to improve medication adherence are limited in this population. To review the state of the literature on the types and efficacy of psychosocial interventions for improving antidepressant pharmacotherapy adherence in depressed and anxious older adults. We conducted a scoping review according to PRISMA-ScR guidelines. PubMed/Medline and article references starting in 1980 up to 28 February 2023 were reviewed...
2023: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/38022837/prevalence-and-predictors-of-inappropriate-prescribing-in-outpatients-with-severe-mental-illness
#11
JOURNAL ARTICLE
Lisanne Koomen, Ilona van de Meent, Floor Elferink, Ingeborg Wilting, Wiepke Cahn
BACKGROUND: Potentially inappropriate prescribing (PIP) is frequent in geriatrics and results in an increased risk for adverse effects, morbidity, mortality and reduced quality of life. Research on PIP in psychiatry has mainly focused on elderly patients and inpatients. OBJECTIVES: To determine the prevalence and the predictors of PIP of psychotropic medication in outpatients with severe mental illness. DESIGN: This study is part of the Muva study, a pragmatic open Stepped Wedge Cluster Randomized Trial of a physical activity intervention for patients (age ⩾ 16 years) with severe mental illness...
2023: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/38022836/management-of-dyslipidaemia-in-individuals-with-severe-mental-illness-a-population-based-study-in-the-greater-copenhagen-area
#12
JOURNAL ARTICLE
Grimur Høgnason Mohr, Carlo Alberto Barcella, Mia Klinten Grand, Margit Kriegbaum, Volkert Siersma, Margaret K Hahn, Sri Mahavir Agarwal, Catrine Bakkedal, Lone Baandrup, Filip Krag Knop, Christen Lykkegaard Andersen, Bjørn Hylsebeck Ebdrup
BACKGROUND: Severe mental illness (SMI) is associated with increased cardiovascular risk. Dyslipidaemia is a potentially modifiable risk factor, which may be inadequately managed in patients with SMI. OBJECTIVES: To assess management of dyslipidaemia in patients with SMI versus healthy controls (HCs) in 2005 and 2015. DESIGN AND METHODS: Using Danish registers, we identified adult patients with SMI in the Greater Copenhagen Area (schizophrenia spectrum disorders or bipolar disorder) with ⩾1 general practitioner contact in the year before 2005 and 2015, respectively, and HCs without SMI matched on age and gender (1:5)...
2023: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/38022835/a-6-week-phase-iib-randomized-double-blind-placebo-controlled-trial-of-anyu-peibo-capsules-for-the-treatment-of-major-depressive-disorder-in-adults
#13
JOURNAL ARTICLE
Shen He, Yimin Yu, Jingjing Huang, Jiahui Yin, Yajuan Niu, Yazhou Lu, Bin Wu, Maosheng Fang, Xue Wang, Zhiping Tao, Lehua Li, Kan Li, Yan Li, Xiujuan Ding, Yifeng Shen, Huafang Li
BACKGROUND: Almost one-third of patients with major depressive disorder (MDD) do not respond to conventional antidepressants, and new treatments for MDD are urgently needed. OBJECTIVES: This phase IIb clinical trial was designed to evaluate the efficacy and safety of Anyu Peibo capsules in the treatment of adults with MDD. DESIGN: A multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study. METHODS: A total of 172 patients with MDD from nine study centers were randomized (1:1) to receive placebo ( n  = 86) or oral Anyu Peibo capsules (0...
2023: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/38022834/optimizing-treatment-for-older-adults-with-depression
#14
REVIEW
Maytinee Srifuengfung, Bethany R Tellor Pennington, Eric J Lenze
This review presents a comprehensive guide for optimizing medication management in older adults with depression within an outpatient setting. Medication optimization involves tailoring the antidepressant strategy to the individual, ensuring the administration of appropriate medications at optimal dosages. In the case of older adults, this process necessitates not only adjusting or changing antidepressants but also addressing the concurrent use of inappropriate medications, many of which have cognitive side effects...
2023: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/37915364/efficacy-of-intraoperative-subanesthetic-dose-of-ketamine-esketamine-in-preventing-postoperative-cognitive-dysfunction-a-systematic-review-and-meta-analysis
#15
JOURNAL ARTICLE
Na Zhou, Chengchuan Chen, Yubei Liu, Zhaolan Yu, Yanhua Chen
BACKGROUND: Postoperative cognitive dysfunction (POCD) is a common complication after anesthesia surgery, especially in older people, that can persist weeks or months after surgery as a short-term impairment of cognitive abilities, or even for a prolonged duration over years, potentially progressing into permanent cognitive dysfunction. However, the pathogenesis of POCD is not fully understood, and therefore an optimal solution for preventing POCD has yet to be established. Some studies have shown that intraoperative ketamine/esketamine reduces the incidence of POCD, but this remains controversial...
2023: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/37786804/comparative-effectiveness-study-of-paliperidone-palmitate-6-month-with-a-real-world-external-comparator-arm-of-paliperidone-palmitate-1-month-or-3-month-in-patients-with-schizophrenia
#16
JOURNAL ARTICLE
Ibrahim Turkoz, Joshua Wong, Benjamin Chee, Uzma Siddiqui, R Karl Knight, Ute Richarz, Christoph U Correll
BACKGROUND: The paliperidone palmitate 6-month (PP6M) long-acting injectable formulation is currently the longest dosing interval available for schizophrenia treatment. OBJECTIVE: To compare treatment outcomes between a real-world external comparator arm (ECA; NeuroBlu database) and the PP6M open-label extension (OLE) clinical trial arm. METHODS: The ECA comprised patients receiving PP 1-month (PP1M) or PP 3-month (PP3M) for ⩾12 months without a relapse...
2023: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/37781686/hypercoagulable-state-in-patients-with-schizophrenia-different-effects-of-acute-and-chronic-antipsychotic-medications
#17
JOURNAL ARTICLE
Caiji Zheng, Haiyan Liu, Weifeng Tu, Lingyun Lin, Haiyun Xu
BACKGROUND: Previous studies reported higher incidences of venous thromboembolism and cardiovascular disease in schizophrenia patients and higher indicators of thrombosis, thrombocyte activation, and platelet dysfunction. OBJECTIVES: To check if first-episode schizophrenia (FES) patients have a hypercoagulable state and determine whether acute and chronic antipsychotics have the same effect on blood coagulation or fibrinolysis-related biomarkers. DESIGN: Case-control study...
2023: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/37771417/ketamine-for-bipolar-depression-an-updated-systematic-review
#18
JOURNAL ARTICLE
Farhan Fancy, Sipan Haikazian, Danica E Johnson, David C J Chen-Li, Anastasia Levinta, Muhammad I Husain, Rodrigo B Mansur, Joshua D Rosenblat
BACKGROUND: The therapeutic potential of subanesthetic doses of ketamine appears promising in unipolar depression; however, its effectiveness in treating bipolar depression (BD) remains uncertain. OBJECTIVE: This systematic review aimed to summarize findings on the use of ketamine for the treatment of BD by assessing its efficacy, safety, and tolerability. DESIGN: Systematic review. METHODS: We conducted a systematic review of studies that investigated the use of ketamine for adults with BD...
2023: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/37766730/history-repeating-guidelines-to-address-common-problems-in-psychedelic-science
#19
REVIEW
Michiel van Elk, Eiko I Fried
Research in the last decade has expressed considerable optimism about the clinical potential of psychedelics for the treatment of mental disorders. This optimism is reflected in an increase in research papers, investments by pharmaceutical companies, patents, media coverage, as well as political and legislative changes. However, psychedelic science is facing serious challenges that threaten the validity of core findings and raise doubt regarding clinical efficacy and safety. In this paper, we introduce the 10 most pressing challenges, grouped into easy, moderate, and hard problems...
2023: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/37719449/implementing-gradual-hyperbolic-tapering-of-long-acting-injectable-antipsychotics-by-prolonging-the-inter-dose-interval-an-in-silico-modelling-study
#20
REVIEW
James R O'Neill, David M Taylor, Mark A Horowitz
Gradual, hyperbolic tapering has been proposed as a method to reduce the risk of withdrawal effects and potential relapse of an underlying condition by minimising disruption of existing equilibria. We applied hyperbolic tapering principles in silico to long-acting aripiprazole to generate regimens for withdrawal in clinical practice. We derived thresholds for taper rates using existing studies and consensus. Using pharmacokinetic data for aripiprazole long-acting injectable antipsychotic (ALAI), we conducted in silico modelling to examine the impact of abrupt cessation of long-acting injectable antipsychotic (LAI) medication and the effect of prolonging inter-dose interval on plasma aripiprazole levels and consequent D2 occupancy...
2023: Therapeutic Advances in Psychopharmacology
journal
journal
43489
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.